Sustained Release Implant

The iDose TR demonstrated sustained IOP reduction at 36 months, according to a press release from Glaukos.

NEW YORK — Sustained-release drug delivery for glaucoma treatment offers a way to reduce IOP without relying on surgery or drops and gives physicians a way to customize treatment plans for individual patients, according to a speaker here.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Nancy Lurker, CEO of EyePoint Pharmaceuticals, discusses recent advancements and the potential of sustained-release drug delivery technology in ophthalmology.

WAILEA, Hawaii — In this video from Hawaiian Eye, Jay S. Duker, MD, chief strategic scientific officer at EyePoint, discusses the development of a long-acting, sustained release, bio-erodible implant for the treatment of retinal disease.

Due to COVID-19, my practice only saw urgent or emergent patients at risk of going blind for 3 months in early 2020. Once we began to accept patients for routine in-person visits again, we worked to optimize treatment for a COVID-19 world.

New surgical options, novel therapeutics and the merging of technologies will continue to define the future of glaucoma management, according to George A. Cioffi, MD, keynote speaker at the virtual Glaucoma 360 New Horizons Forum.

Subjects treated with OTX-TIC demonstrated a mean reduction in IOP from baseline of 7 mm Hg to 11 mm Hg as early as 2 days after administration, according to interim phase 1 clinical trial results presented by Ocular Therapeutix.

Two IOP reduction methods from Glaukos showed favorable results and safety profiles in recent trials, according to company press releases.

The impact of COVID-19 on health care dominated the news in 2020, including glaucoma care. Also popular were advances in both medical and surgical treatments for glaucoma.

PolyActiva has completed a phase 1 clinical study evaluating the Latanoprost FA SR ocular implant for glaucoma treatment, according to a press release.